Covered recipient · General Payments record
THOMAS J GEORGE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,820.00
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $1,750.00 | 1 |
| Food and Beverage | $70.00 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $1,750.00 | 1 |
| Merck Sharp & Dohme LLC | $70.00 | 2 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
THOMAS J GEORGE
NPI 1104867365 · CMS profile ID 321938
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
GAINESVILLE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $1,820.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.00 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141839417 | CMS |
| Merck Sharp & Dohme LLC | $35.00 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141713026 | CMS |
| PFIZER INC. | $1,750.00 | 03/06/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131470386 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $507,584.60 | 83 |
| PY2024 | Recipient | $2,598.05 | 11 |
| PY2024 | Principal investigator | $596,039.96 | 28 |
| PY2023 | Principal investigator | $1,130,234.11 | 90 |
| PY2022 | Principal investigator | $1,675,365.46 | 75 |
| PY2021 | Principal investigator | $2,129,940.43 | 124 |
| PY2020 | Principal investigator | $2,169,106.03 | 143 |
| PY2019 | Principal investigator | $2,064,075.98 | 203 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
203 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,429.45 | 12/31/2019 | Non-covered Recipient Entity University Of Florida | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 684995233 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $969.57 | 12/31/2019 | Non-covered Recipient Entity University Of Florida Health Womens Health Specialists | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 684995267 |
| Principal investigator 1 | Seattle Genetics, Inc. | $1,248.00 | 12/11/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825077 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $235,740.12 | 12/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | 0000000000000000000000000000000000000000000000000000000000000000214456 | No dispute reported | 06/30/2026 | 965534673 |
| Principal investigator 1 | Amgen Inc. | $6,064.00 | 11/27/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA HEALTH | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. | No dispute reported | 06/30/2026 | 675795239 |
| Principal investigator 1 | Incyte Corporation | $5,618.00 | 11/27/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436753 |
| Principal investigator 1 | Incyte Corporation | $4,805.00 | 11/12/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436747 |
| Principal investigator 1 | Incyte Corporation | $12,980.00 | 11/12/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436749 |
| Principal investigator 1 | Incyte Corporation | $3,610.00 | 11/12/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436751 |
| Principal investigator 1 | Incyte Corporation | $4.84 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436675 |
| Principal investigator 1 | Incyte Corporation | $0.18 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436677 |
| Principal investigator 1 | Incyte Corporation | $101.70 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436679 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436681 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436683 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436685 |
| Principal investigator 1 | Incyte Corporation | $47.16 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436687 |
| Principal investigator 1 | Incyte Corporation | $565.74 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436689 |
| Principal investigator 1 | Incyte Corporation | $46.80 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436691 |
| Principal investigator 1 | Incyte Corporation | $65.14 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436693 |
| Principal investigator 1 | Incyte Corporation | $185.20 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436695 |
| Principal investigator 1 | Incyte Corporation | $22.80 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436697 |
| Principal investigator 1 | Incyte Corporation | $94.32 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436699 |
| Principal investigator 1 | Incyte Corporation | $81.36 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436701 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436709 |
| Principal investigator 1 | Incyte Corporation | $23.40 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436711 |
| Principal investigator 1 | Incyte Corporation | $46.80 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436713 |
| Principal investigator 1 | Incyte Corporation | $19.10 | 11/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436715 |
| Principal investigator 1 | Incyte Corporation | $2,070.90 | 11/05/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436743 |
| Principal investigator 1 | Incyte Corporation | $5,796.00 | 11/05/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436745 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $171,447.36 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | 0000000000000000000000000000000000000000000000000000000000000000214456 | No dispute reported | 06/30/2026 | 965534675 |
| Principal investigator 1 | TESARO, Inc. | $24,828.76 | 10/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | UF-STO-ETI-001 THOMAS GEORGE | No dispute reported | 06/30/2026 | 689413731 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,553.10 | 10/21/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer | No dispute reported | 06/30/2026 | 691533243 |
| Principal investigator 1 | Seattle Genetics, Inc. | $9,473.10 | 10/21/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825079 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $246.69 | 10/16/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer | No dispute reported | 06/30/2026 | 691398215 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $246.69 | 10/16/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer | No dispute reported | 06/30/2026 | 691504003 |
| Principal investigator 1 | Incyte Corporation | $64.00 | 10/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436755 |
| Principal investigator 1 | Incyte Corporation | $64.00 | 10/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436757 |
| Principal investigator 1 | Incyte Corporation | $44.80 | 10/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436759 |
| Principal investigator 1 | Incyte Corporation | $18,850.50 | 10/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436741 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,366.00 | 10/02/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825075 |
| Principal investigator 1 | Amgen Inc. | $4,109.51 | 09/24/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. | No dispute reported | 06/30/2026 | 675795203 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 09/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436727 |
| Principal investigator 1 | Incyte Corporation | $2,752.00 | 09/17/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436733 |
| Principal investigator 1 | Incyte Corporation | $960.00 | 09/17/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436735 |
| Principal investigator 1 | Incyte Corporation | $704.00 | 09/17/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436737 |
| Principal investigator 1 | Incyte Corporation | $640.00 | 09/17/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436739 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $200.00 | 09/13/2019 | Non-covered Recipient Entity University Of Florida | Clinical Study Site Agreement | No dispute reported | 06/30/2026 | 629172715 |
| Principal investigator 1 | Incyte Corporation | $15.20 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436599 |
| Principal investigator 1 | Incyte Corporation | $3.08 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436601 |
| Principal investigator 1 | Incyte Corporation | $0.27 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436603 |
| Principal investigator 1 | Incyte Corporation | $70.74 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436605 |
| Principal investigator 1 | Incyte Corporation | $61.02 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436607 |
| Principal investigator 1 | Incyte Corporation | $34.20 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436609 |
| Principal investigator 1 | Incyte Corporation | $11.70 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436611 |
| Principal investigator 1 | Incyte Corporation | $9.55 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436613 |
| Principal investigator 1 | Incyte Corporation | $45.60 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436631 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436633 |
| Principal investigator 1 | Incyte Corporation | $35.10 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436635 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436637 |
| Principal investigator 1 | Incyte Corporation | $60.15 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436639 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436641 |
| Principal investigator 1 | Incyte Corporation | $117.90 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436643 |
| Principal investigator 1 | Incyte Corporation | $45.60 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436659 |
| Principal investigator 1 | Incyte Corporation | $35.10 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436661 |
| Principal investigator 1 | Incyte Corporation | $15.20 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436663 |
| Principal investigator 1 | Incyte Corporation | $11.70 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436665 |
| Principal investigator 1 | Incyte Corporation | $15.20 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436667 |
| Principal investigator 1 | Incyte Corporation | $11.70 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436669 |
| Principal investigator 1 | Incyte Corporation | $9.55 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436671 |
| Principal investigator 1 | Incyte Corporation | $11.70 | 09/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436673 |
| Principal investigator 1 | Incyte Corporation | $11,208.60 | 09/05/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436725 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,600.00 | 08/28/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825039 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $500.00 | 08/14/2019 | Non-covered Recipient Entity UNVIERSITY OF FLORIDA | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. | No dispute reported | 06/30/2026 | 691456479 |
| Principal investigator 1 | Incyte Corporation | $3.72 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436469 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436471 |
| Principal investigator 1 | Incyte Corporation | $232.98 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436473 |
| Principal investigator 1 | Incyte Corporation | $11.96 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436475 |
| Principal investigator 1 | Incyte Corporation | $132.21 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436477 |
| Principal investigator 1 | Incyte Corporation | $2.13 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436479 |
| Principal investigator 1 | Incyte Corporation | $0.60 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436481 |
| Principal investigator 1 | Incyte Corporation | $0.96 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436483 |
| Principal investigator 1 | Incyte Corporation | $372.42 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436485 |
| Principal investigator 1 | Incyte Corporation | $140.64 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436487 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436489 |
| Principal investigator 1 | Incyte Corporation | $40.86 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436491 |
| Principal investigator 1 | Incyte Corporation | $5.60 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436493 |
| Principal investigator 1 | Incyte Corporation | $95.50 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436495 |
| Principal investigator 1 | Incyte Corporation | $0.26 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436535 |
| Principal investigator 1 | Incyte Corporation | $11.70 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436537 |
| Principal investigator 1 | Incyte Corporation | $30.40 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436539 |
| Principal investigator 1 | Incyte Corporation | $172.89 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436541 |
| Principal investigator 1 | Incyte Corporation | $21.06 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436543 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436545 |
| Principal investigator 1 | Incyte Corporation | $100.25 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436547 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436615 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436617 |
| Principal investigator 1 | Incyte Corporation | $317.70 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436619 |
| Principal investigator 1 | Incyte Corporation | $117.90 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436621 |
| Principal investigator 1 | Incyte Corporation | $1,117.26 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436623 |
| Principal investigator 1 | Incyte Corporation | $565.74 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436625 |
| Principal investigator 1 | Incyte Corporation | $70.50 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436627 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436629 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436645 |
| Principal investigator 1 | Incyte Corporation | $140.64 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436647 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436649 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436651 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436653 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436655 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 08/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy | No dispute reported | 06/30/2026 | 708436657 |
| Principal investigator 1 | Amgen Inc. | $77.25 | 08/01/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543. | No dispute reported | 06/30/2026 | 675795201 |
| Principal investigator 1 | Incyte Corporation | $320.00 | 07/25/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436731 |
| Principal investigator 1 | Seattle Genetics, Inc. | $15,744.30 | 07/16/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825043 |
| Principal investigator 1 | Incyte Corporation | $2,758.00 | 07/11/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436729 |
| Principal investigator 1 | Incyte Corporation | $260.00 | 07/02/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436723 |
| Principal investigator 1 | Seattle Genetics, Inc. | $8,463.00 | 07/02/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678825045 |
| Principal investigator 1 | Incyte Corporation | $3,200.00 | 06/11/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436719 |
| Principal investigator 1 | Incyte Corporation | $2,464.00 | 06/11/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436721 |
| Principal investigator 1 | Incyte Corporation | $111.12 | 06/10/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436443 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 06/04/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436717 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $296,598.34 | 06/01/2019 | Non-covered Recipient Entity National Surgical Adjuvant Breast And Bowel Project Foundation, Inc | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer | No dispute reported | 06/30/2026 | 684986195 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 05/28/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436593 |
| Principal investigator 1 | Incyte Corporation | $228.00 | 05/28/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436595 |
| Principal investigator 1 | Incyte Corporation | $488.00 | 05/28/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436597 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,650.00 | 05/24/2019 | Non-covered Recipient Entity University Of Florida Health Womens Health Specialists | A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy | No dispute reported | 06/30/2026 | 684995237 |
| Principal investigator 1 | Incyte Corporation | $607,078.75 | 05/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436583 |
| Principal investigator 1 | Incyte Corporation | $9,315.00 | 05/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436585 |
| Principal investigator 1 | Incyte Corporation | $5,766.00 | 05/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436587 |
| Principal investigator 1 | Incyte Corporation | $3,844.00 | 05/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436589 |
| Principal investigator 1 | Incyte Corporation | $4,461.00 | 05/23/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436591 |
| Principal investigator 1 | Seattle Genetics, Inc. | $988.00 | 05/22/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824985 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $85,723.68 | 05/21/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | 0000000000000000000000000000000000000000000000000000000000000000214456 | No dispute reported | 06/30/2026 | 965534677 |
| Principal investigator 1 | Incyte Corporation | $3,764.70 | 05/21/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436581 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,583.60 | 05/15/2019 | Non-covered Recipient Entity University Of Florida Health Womens Health Specialists | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 684995245 |
| Principal investigator 1 | Incyte Corporation | $147.00 | 05/14/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436573 |
| Principal investigator 1 | Incyte Corporation | $1,024.00 | 05/14/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436575 |
| Principal investigator 1 | Incyte Corporation | $192.00 | 05/14/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436577 |
| Principal investigator 1 | Incyte Corporation | $4,015.00 | 05/14/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436579 |
| Principal investigator 1 | Incyte Corporation | $0.75 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436397 |
| Principal investigator 1 | Incyte Corporation | $1.28 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436399 |
| Principal investigator 1 | Incyte Corporation | $38.20 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436401 |
| Principal investigator 1 | Incyte Corporation | $38.39 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436403 |
| Principal investigator 1 | Incyte Corporation | $2.48 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436405 |
| Principal investigator 1 | Incyte Corporation | $1.76 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436407 |
| Principal investigator 1 | Incyte Corporation | $0.30 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436409 |
| Principal investigator 1 | Incyte Corporation | $377.16 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436411 |
| Principal investigator 1 | Incyte Corporation | $58.50 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436413 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436415 |
| Principal investigator 1 | Incyte Corporation | $35.10 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436417 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436419 |
| Principal investigator 1 | Incyte Corporation | $70.20 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436421 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436423 |
| Principal investigator 1 | Incyte Corporation | $282.96 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436425 |
| Principal investigator 1 | Incyte Corporation | $1.98 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436427 |
| Principal investigator 1 | Incyte Corporation | $21.34 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436429 |
| Principal investigator 1 | Incyte Corporation | $13.64 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436431 |
| Principal investigator 1 | Incyte Corporation | $45.60 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436433 |
| Principal investigator 1 | Incyte Corporation | $152.55 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436435 |
| Principal investigator 1 | Incyte Corporation | $136.80 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436437 |
| Principal investigator 1 | Incyte Corporation | $1.08 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436439 |
| Principal investigator 1 | Incyte Corporation | $162.72 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436441 |
| Principal investigator 1 | Incyte Corporation | $0.30 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436445 |
| Principal investigator 1 | Incyte Corporation | $2.48 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436447 |
| Principal investigator 1 | Incyte Corporation | $38.39 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436449 |
| Principal investigator 1 | Incyte Corporation | $0.75 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436451 |
| Principal investigator 1 | Incyte Corporation | $1.28 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436453 |
| Principal investigator 1 | Incyte Corporation | $47.75 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436455 |
| Principal investigator 1 | Incyte Corporation | $35.10 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436457 |
| Principal investigator 1 | Incyte Corporation | $1.28 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436459 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436461 |
| Principal investigator 1 | Incyte Corporation | $35.10 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436463 |
| Principal investigator 1 | Incyte Corporation | $28.65 | 05/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436465 |
| Principal investigator 1 | Taiho Oncology, Inc. | $3,743.00 | 04/25/2019 | Non-covered Recipient Entity University of Florida | TAS 120 | No dispute reported | 06/30/2026 | 681433259 |
| Principal investigator 1 | Seattle Genetics, Inc. | $32,002.10 | 04/18/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824983 |
| Principal investigator 1 | Seattle Genetics, Inc. | $2,860.00 | 04/03/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824975 |
| Principal investigator 1 | Seattle Genetics, Inc. | $3,420.14 | 04/03/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824977 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,950.00 | 03/29/2019 | Non-covered Recipient Entity University Of Florida Health Womens Health Specialists | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer | No dispute reported | 06/30/2026 | 684995241 |
| Principal investigator 1 | Seattle Genetics, Inc. | $260.00 | 03/27/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824979 |
| Principal investigator 1 | Taiho Oncology, Inc. | $1,902.00 | 03/21/2019 | Non-covered Recipient Entity University of Florida | TAS-102-107 | No dispute reported | 06/30/2026 | 681433193 |
| Principal investigator 1 | Taiho Oncology, Inc. | $5,997.00 | 03/21/2019 | Non-covered Recipient Entity University of Florida | TAS-102-107 | No dispute reported | 06/30/2026 | 681433197 |
| Principal investigator 1 | Incyte Corporation | $26,227.00 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436549 |
| Principal investigator 1 | Incyte Corporation | $2,752.00 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436551 |
| Principal investigator 1 | Incyte Corporation | $960.00 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436553 |
| Principal investigator 1 | Incyte Corporation | $704.00 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436555 |
| Principal investigator 1 | Incyte Corporation | $640.00 | 03/19/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy | No dispute reported | 06/30/2026 | 708436557 |
| Principal investigator 1 | Eli Lilly and Company | $23,990.00 | 03/12/2019 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER | No dispute reported | 06/30/2026 | 654298667 |
| Principal investigator 1 | Celgene Corporation | $2,240.00 | 03/08/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase III Study - PANC-003 (BMS Study Number: CA139-P15) (ABI-007-PANC-003) | No dispute reported | 06/30/2026 | 675419521 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,030.08 | 03/07/2019 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma | No dispute reported | 06/30/2026 | 691325249 |
| Principal investigator 1 | Incyte Corporation | $4,160.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436561 |
| Principal investigator 1 | Incyte Corporation | $2,438.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436563 |
| Principal investigator 1 | Incyte Corporation | $12,675.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 708436565 |
| Principal investigator 1 | Incyte Corporation | $6,272.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436567 |
| Principal investigator 1 | Incyte Corporation | $10,626.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436569 |
| Principal investigator 1 | Incyte Corporation | $320.00 | 02/26/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436571 |
| Principal investigator 1 | Eli Lilly and Company | $131.25 | 02/25/2019 | Non-covered Recipient Entity DERMATOLOGY INSTITUTE AND SKIN CARE | RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER | No dispute reported | 06/30/2026 | 654293703 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,500.00 | 02/21/2019 | Non-covered Recipient Entity University Of Florida | A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy | No dispute reported | 06/30/2026 | 684995207 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $29,512.00 | 02/20/2019 | Non-covered Recipient Entity University Of Florida Board Of Trustees | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | No dispute reported | 06/30/2026 | 639758213 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $12,456.96 | 01/29/2019 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma | No dispute reported | 06/30/2026 | 691311333 |
| Principal investigator 1 | Incyte Corporation | $26,674.00 | 01/22/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 708436559 |
| Principal investigator 1 | Taiho Oncology, Inc. | $1,952.00 | 01/22/2019 | Non-covered Recipient Entity University of Florida | TAS-102-107 | No dispute reported | 06/30/2026 | 681433195 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $151,556.97 | 01/16/2019 | Non-covered Recipient Entity University Of Florida | MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial | No dispute reported | 06/30/2026 | 684995216 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,500.00 | 01/11/2019 | Non-covered Recipient Entity University Of Florida | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer | No dispute reported | 06/30/2026 | 684995211 |
| Principal investigator 1 | Seattle Genetics, Inc. | $21,775.00 | 01/09/2019 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 678824973 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,114.24 | 01/08/2019 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma | No dispute reported | 06/30/2026 | 691311157 |